Roche keeps 2026 outlook as Q3 sales rise 7% at constant currencies
FROM THE WIRE · FINANCE.YAHOO.COM
Investing.com -- Roche on Thursday kept its full-year outlook unchanged after third-quarter sales rose 7% at constant currencies, helped by strong demand for its multiple sclerosis, eye and allergy drugs. Still guessing which stocks will beat the market? Our AI portfolio updates…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishGrowing sales, unchanged outlook and an expected dividend increase make a favorable backdrop for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Third-quarter sales rose 7% at constant currencies and 8% in Swiss francs.
- 02For nine months group sales rose 6% at constant rates to CHF 46.49 billion.
- 03Roche expects to raise its dividend in Swiss francs again.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets